Abstract 6511: Androgen receptor (AR) genomic alterations and clinical outcome with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy
Michael Sun(Cornell University), Scott T. Tagawa(Cornell University), Paul J. Christos(Cornell University), David M. Nanus(Cornell University), Joseph R. Osborne(Cornell University), Cora N. Sternberg(Cornell University), Panagiotis J. Vlachostergios(NewYork–Presbyterian Hospital), Kristine Peregrino Lacuna(Memorial Sloan Kettering Cancer Center), Neil H. Bander(Convergent Science (United States)), Ariel Schaap(Cornell University), Charlene Thomas(Cornell University), Muhammad Junaid Niaz(Cornell University), Ana M. Molina(Cornell University)
Cited by 3
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
|The Lancet|2002|1.7k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin
|New England Journal of Medicine|1997|1.6k